Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 6/20 | 0.58 |
| ▸ | CALCR | P30988 | 4/20 | 0.54 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 4/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.48 |
| ▸ | CCKBR | P32239 | 1/20 | 0.47 |
| ▸ | GLP1R | P43220 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31182876 | 0.89 | CALCR (0.55) | CALCRLCALCRCRHR1CRHR2F2 | |
| SCHEMBL30974474 | 0.88 | CALCRL (0.59) | CALCRLCALCRCRHR1CRHR2RAMP1 | |
| SCHEMBL31182805 | 0.85 | CALCR (0.67) | CALCRCRHR1CRHR2F2 | |
| SCHEMBL30974077 | 0.85 | EPHA2 (0.57) | CALCRLCALCRF2C5AR1GLP1R | |
| SCHEMBL30431276 | 0.85 | CALCR (0.64) | CALCRLCALCRCRHR1CRHR2F2 | |
| SCHEMBL31073576 | 0.85 | CALCR (0.62) | CALCRCRHR1CRHR2F2C5AR1 | |
| SCHEMBL31519878 | 0.84 | SLC6A2 (0.54) | F2C5AR1 | |
| SCHEMBL31182512 | 0.84 | CALCR (0.64) | CALCRCRHR1CRHR2F2CCKBR | |
| SCHEMBL31527736 | 0.83 | F2 (0.56) | CALCRLCALCRCRHR1CRHR2F2 | |
| SCHEMBL31688311 | 0.83 | CALCR (0.59) | CALCRLCALCRCRHR1CRHR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12303916-B2 | Peptide and method for using same | SHIBAURA INSTITUTE OF TECHNOLOGY (JP) | 2025-05-20 | — | — | US | disclosed |
| US-20230285986-A1 | NOVEL PEPTIDE AND METHOD FOR USING SAME | SHIBAURA INSTITUTE OF TECHNOLOGY (JP) | 2023-09-14 | — | — | US | disclosed |
| US-11254707-B2 | Peptide binding to arsenic-containing mineral and use thereof | SHIBAURA INSTITUTE OF TECHNOLOGY (JP) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254707-B2 | Peptide binding to arsenic-containing mineral and use thereof | AS3MT, GC, TTR | CALCRL 673/4885CALCR 764/4885CRHR1 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.